IL-4/IL-13 pathway in nasal type 2 inflammation: the central role and targeted therapy

Key Findings

• ●IL-4Rα/STAT6 axis central to CRSwNP
• ●IL-4/IL-13 drive IgE class switching, mucus production, barrier disruption
• ●Dupilumab blocks both pathways simultaneously

Referenced in (1 disease)

No validation events recorded yet. Source will be checked on the next kipine-source-validator run.